Recent clinical trials have demonstrated that the use of PARP inhibitors—a nonchemotherapy-targeted treatment option—has significantly improved clinical and patient-reported outcomes with a manageable side effect profile in patients with HER2-negative ABC carrying a germline BRCA1/2 mutation (12, 15, 16). The gene discussed is ERBB2; the disease is aneurysmal bone cyst.